Expression of MUC1-CE has also been linked with chemoresistance and disease progression (Tinder et al. 2008; Jonckheere et al. 2010; Suh et al. 2017), thus targeting of MUC1-CE positive pancreatic cancer cells could have value in treating advanced PDAC. This evidence concerns the gene MUC1 and familial pancreatic carcinoma.